Vantive Highlights Late-Breaking High Clinical Impact Data at ERA Indicating HDx Therapy is a Practical Alternative to Online Hemodiafiltration
· Financial Post
GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized controlled MOTheR trial and interim results from the real-world CONCORDIA study were presented at the 63rd European Renal Association (ERA) Congress, held June 3-6, 2026, in Glasgow, Scotland. Read More
Visit asg-reflektory.pl for more information.